Page 6 - CUA KIDNEY CANCER HANDBOOK 2020
P. 6
Table of contents (con’t’d)
Treatment Sequencing 45
Considerations for Treatment Selection 45
Real-world Evidence (IMDC) 45
Drug Therapy 49
Immunotherapy Agents 49
Avelumab (BAVENCIO ) 49
®
Ipilimumab (YERVOY ) 51
®
®
Nivolumab (OPDIVO ) 53
Pembrolizumab (KEYTRUDA ) 56
®
Anti-angiogenic Therapy (VEGF Receptor TKIs) 58
Axitinib (INLYTA ) 58
®
Cabozantinib (CABOMETYX ) 60
TM
®
Lenvatinib (LENVIMA ) 62
®
Pazopanib (VOTRIENT ) 64
Sunitinib (SUTENT ) 67
®
mTOR-targeted Agents 69
Everolimus (AFINITOR ) 69
®
Managing Toxicities 71
Immune-related Adverse Events (IrAEs) 71
General IrAE Management Principles 71
Baseline Assessment 71
Rash/Inflammatory Dermatitis IrAE 72
Colitis IrAE 73
Pneumonitis IrAE 75
Hypothyroidism IrAE 76
Inflammatory Arthritis IrAE 77
Other IrAEs to Watch For 78
Resources 79
Prognostic Scoring – IMDC criteria 79
ECOG Performance Status 80
Acronyms and Abbreviations 81
References 83
4 Practical Approaches to Managing Advanced Kidney Cancer